Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report report published on Thursday morning. The brokerage issued a hold rating on the medical research company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research report on Monday, November 11th.

Cytosorbents Trading Up 13.4 %

Shares of NASDAQ CTSO opened at $1.01 on Thursday. The business has a 50 day simple moving average of $0.98 and a 200 day simple moving average of $1.02. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $2.15. The stock has a market cap of $55.23 million, a price-to-earnings ratio of -2.81 and a beta of 0.57. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Hedge Funds Weigh In On Cytosorbents

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sargent Investment Group LLC boosted its holdings in shares of Cytosorbents by 13.4% during the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock worth $2,439,000 after buying an additional 192,747 shares during the period. Atomi Financial Group Inc. bought a new stake in Cytosorbents during the third quarter valued at about $51,000. Geode Capital Management LLC boosted its holdings in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after acquiring an additional 32,415 shares during the period. Finally, CM Management LLC grew its position in shares of Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.